Literature DB >> 26340336

Genetic variation in the human cytochrome P450 supergene family.

Kohei Fujikura1, Magnus Ingelman-Sundberg, Volker M Lauschke.   

Abstract

OBJECTIVES: Single nucleotide variations (SNVs) in the cytochrome P450 (CYP) gene family are a primary cause of interindividual differences in therapeutic effects and adverse reactions to drugs. However, we still lack important information on the extent of CYP polymorphisms at the population level. Here, we developed a comprehensive data set of SNVs in all 57 human CYP genes by integrating data from two extensive population sequencing projects and analyzed the distribution of SNVs in different subpopulations.
MATERIALS AND METHODS: CYP genetic variants derived from the NHLBI and 1000 Genomes project were classified by variant type, frequency, and ethnic origins. The genetic variability of CYP genes was normalized on the basis of nonlinear regression and the total number of genetic variations was estimated by the derived formulas.
RESULTS: In total, we detected 6165 SNVs, of which many were novel. The vast majority (83.2%) of all SNVs in coding regions were very rare (minor allele frequency <0.1%). On the basis of the regression analysis, the total number of genetic variations in human CYP genes was calculated to be 3.4 × 10 and 4.8 × 10 for a population size of one million in Europeans and Africans, respectively.
CONCLUSION: Our results suggest that the variant spectrum of human CYP genes is extensive and only a fraction of SNVs has been characterized to date. Moreover, the multitude of very rare novel sequence variants indicates that the commonly used SNV platforms are not satisfactory for determining the true genotype, which is critical information for personalized treatment with drugs influenced by CYP polymorphisms.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26340336     DOI: 10.1097/FPC.0000000000000172

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  51 in total

Review 1.  Essential Characteristics of Pharmacogenomics Study Publications.

Authors:  Caroline F Thorn; Michelle Whirl-Carrillo; Houda Hachad; Julie A Johnson; Ellen M McDonagh; Mark J Ratain; Mary V Relling; Stuart A Scott; Russ B Altman; Teri E Klein
Journal:  Clin Pharmacol Ther       Date:  2019-01       Impact factor: 6.875

Review 2.  Emerging strategies to bridge the gap between pharmacogenomic research and its clinical implementation.

Authors:  Volker M Lauschke; Magnus Ingelman-Sundberg
Journal:  NPJ Genom Med       Date:  2020-03-05       Impact factor: 8.617

Review 3.  The Role of Next-Generation Sequencing in Pharmacogenetics and Pharmacogenomics.

Authors:  Ute I Schwarz; Markus Gulilat; Richard B Kim
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

Review 4.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

Review 5.  Environmental mechanisms of orofacial clefts.

Authors:  Michael A Garland; Kurt Reynolds; Chengji J Zhou
Journal:  Birth Defects Res       Date:  2020-10-30       Impact factor: 2.344

Review 6.  Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments.

Authors:  Volker M Lauschke; Lili Milani; Magnus Ingelman-Sundberg
Journal:  AAPS J       Date:  2017-11-27       Impact factor: 4.009

7.  Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism.

Authors:  Julie-Anne Tanner; Andy Z Zhu; Katrina G Claw; Bhagwat Prasad; Viktoriya Korchina; Jianhong Hu; HarshaVardhan Doddapaneni; Donna M Muzny; Erin G Schuetz; Caryn Lerman; Kenneth E Thummel; Steven E Scherer; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2018-01       Impact factor: 2.089

8.  Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences.

Authors:  Meghan J Chenoweth; Jennifer J Ware; Andy Z X Zhu; Christopher B Cole; Lisa Sanderson Cox; Nikki Nollen; Jasjit S Ahluwalia; Neal L Benowitz; Robert A Schnoll; Larry W Hawk; Paul M Cinciripini; Tony P George; Caryn Lerman; Joanne Knight; Rachel F Tyndale
Journal:  Addiction       Date:  2017-11-02       Impact factor: 6.526

9.  Low-frequency variants at the CYP2C9 locus among Puerto Rican patients on warfarin: in silico predictions of functionality and conservation.

Authors:  Karla Claudio-Campos; Mariangeli Moneró-Paredes; Eliud Hernández; Jessicca Renta; Jorge Duconge
Journal:  Pharmacogenomics       Date:  2019-08       Impact factor: 2.533

10.  Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy.

Authors:  Najmeh Ahangari; Mohammad Doosti; Majid Ghayour Mobarhan; Amirhossein Sahebkar; Gordon A Ferns; Alireza Pasdar
Journal:  Ann Med       Date:  2020-08-24       Impact factor: 4.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.